Kerala Ayurveda Q4 FY26 Results: Loss Rs 7.39 Cr

Kerala Ayurveda Q4 FY26 results were declared on May 25, 2026. The company reported net loss of Rs 7.39 crore for the quarter ended March 31, 2026, up 52.0% YoY compared to loss of Rs 15.38 crore in Q4 FY25. Revenue from operations was Rs 34.74 crore, up 10.9% YoY. Results are on a Consolidated basis. Kerala Ayurveda is a Ayurvedic Pharmaceuticals company listed on Indian stock exchanges.

Click Here – Get Free Investment Predictions

Kerala Ayurveda Q4 FY26 Financial Highlights

Metric	Q4 FY26 (Rs Cr)	Q4 FY25 (Rs Cr)	YoY Change
Revenue	Rs 34.74 crore	Rs 31.32 crore	+10.9%
Net Loss	7.39	15.38	+52.0%
Basis	Consolidated

Note: Kerala Ayurveda Q4 FY26 results declared May 25, 2026. Data sourced from Screener.in BSE filings. Verify from audited statements before investment decisions.

Kerala Ayurveda Q4 FY26 Performance Analysis

The Kerala Ayurveda Q4 FY26 results reflect the company’s financial performance during the January to March 2026 quarter. The quarter shows near-term profitability challenges. Kerala Ayurveda operates in the Ayurvedic Pharmaceuticals sector, supported by India’s GDP growth above 6.5% and domestic demand conditions in FY26.

Revenue of Rs 34.74 crore was up 10.9% YoY. Stable revenue reflects consistent business delivery.

Screen the best stocks on the Univest Screener.

Key Factors Driving Kerala Ayurveda Q4 FY26 Results

Revenue and Business Performance

Revenue of Rs 34.74 crore in Kerala Ayurveda Q4 FY26 was up 10.9% YoY. Stable revenue reflects consistent operational delivery. The January to March quarter is the fiscal year-end period characterised by strong execution cycles and year-end activity across Indian companies.

Profitability and Margin Trends

The the business net loss of Rs 7.39 crore up 52.0% YoY. Net loss reflects ongoing operational challenges with FY27 recovery as management’s focus.

India Macro Environment Q4 FY26

India’s macroeconomic environment in Q4 FY26 was supportive with GDP growth above 6.5%, government capex of Rs 11.21 lakh crore budgeted for FY27, and resilient domestic consumption. The Reserve Bank of India’s accommodative stance supported credit conditions. The Ayurvedic Pharmaceuticals sector benefited from these structural tailwinds during the January to March 2026 quarter.

FY27 Outlook

Following the firm results, management guidance on FY27 revenue growth, margin improvement roadmap, and capital allocation priorities will be key investor watchpoints. The Ayurvedic Pharmaceuticals sector continues to benefit from India’s long-term structural growth story. Returning to profitability through operational improvements remains the key FY27 objective.

Download the Univest iOS App or the Univest Android App to get daily stock recommendations and expert research.

Frequently Asked Questions on the company

Investments in securities are subject to market risk. This content is for educational purposes only. Verify all figures from BSE/NSE filings. Consult a SEBI-registered financial advisor.